Satellos Bioscience (NASDAQ:MSLE) Given “Buy” Rating at HC Wainwright

Satellos Bioscience (NASDAQ:MSLE)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 52.80% from the company’s current price.

MSLE has been the subject of a number of other reports. Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating for the company. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Guggenheim initiated coverage on Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price target for the company. Leerink Partners initiated coverage on shares of Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Satellos Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Satellos Bioscience Price Performance

Shares of NASDAQ:MSLE traded up $0.19 on Monday, hitting $7.20. 14,687 shares of the company were exchanged, compared to its average volume of 61,978. Satellos Bioscience has a 1-year low of $4.53 and a 1-year high of $13.39. The stock has a 50 day moving average price of $7.52. The stock has a market cap of $149.96 million, a price-to-earnings ratio of -4.50 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE) last released its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). On average, sell-side analysts forecast that Satellos Bioscience will post -2.29 EPS for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.